Stop the DOAC First in Non-Shock GI Bleeding
In a patient on DOACs after coronary stent placement who develops a non-shock gastrointestinal bleed, you should stop the DOAC while continuing to assess whether antiplatelet therapy can be maintained, particularly if the patient is on aspirin for secondary prevention. 1
Algorithmic Approach to Medication Management
Step 1: Classify the Bleed Severity
Your patient has a non-major bleed since they lack:
- Hemodynamic instability
- Hemoglobin drop ≥2 g/dL
- Requirement for ≥2 units RBCs
- Bleeding at a critical site
Step 2: Initial Medication Management
For non-major bleeds 1:
- Stop the DOAC immediately
- Provide local therapy/manual compression
- Do NOT administer reversal agents (no idarucizumab for dabigatran, no andexanet alfa for rivaroxaban/apixaban) 1, 2
- Provide supportive care and volume resuscitation
- Assess antiplatelet therapy separately - the decision to stop depends on the indication
Step 3: Antiplatelet Decision Tree
If on aspirin for secondary prevention (post-stent):
- Consider continuing aspirin even during the bleed 1, 2
- The 2020 ACC guideline explicitly states to "assess risks and benefits of stopping" antiplatelet therapy in non-major bleeds 1
- If aspirin was interrupted, resume it on the day hemostasis is endoscopically confirmed 2
If on dual antiplatelet therapy (DAPT):
- The decision is more nuanced and depends on timing post-stent
- Recent case evidence suggests de-escalation to single antiplatelet (typically clopidogrel) may be appropriate in the early post-PCI period 3
- The P2Y12 inhibitor is generally the first antiplatelet to discontinue if one must be stopped
Key Clinical Nuances
Why Stop the DOAC First?
The guideline framework prioritizes stopping oral anticoagulation in non-major bleeds while being more conservative about antiplatelet interruption 1. This reflects:
- Reversibility: DOACs have shorter half-lives (6-14 hours) and will clear relatively quickly
- Thrombotic risk: Post-stent patients face significant stent thrombosis risk, particularly within the first 30 days
- Bleeding contribution: The combination of DOAC plus antiplatelet substantially increases bleeding risk 4
Critical Timing Considerations
Time since stent placement matters:
- Within 1 month post-PCI: Stent thrombosis risk is highest; antiplatelet continuation is more critical 3
- Beyond 1 month: More flexibility exists in temporarily holding antiplatelets
- Drug-eluting stents typically require DAPT for at least 6 months, though guidelines vary
Common Pitfalls to Avoid
Don't reflexively give reversal agents: For non-major bleeds with DOACs, reversal agents are NOT recommended and may increase thrombotic complications 1, 2
Don't stop everything simultaneously without thought: The reflex to "stop all blood thinners" ignores the differential thrombotic risks. Post-stent patients need careful risk stratification.
Don't forget PPI therapy: Ensure high-dose PPI therapy is initiated or continued, as this reduces rebleeding risk 5, 2
Don't delay endoscopy: While not requiring emergency endoscopy, these patients need timely evaluation to identify and treat the bleeding source
Restarting Anticoagulation
Once bleeding is controlled:
- Aspirin: Resume same day as confirmed hemostasis 2
- DOAC: Timing depends on rebleeding risk, but typically can restart within days once source is identified and treated 6
- Resuming DOAC therapy after GI bleeding has NOT been associated with increased 90-day thromboembolism risk 6
Risk Factors for Recurrent Bleeding
Monitor for 6:
- Thienopyridine use (3-fold increased rebleeding risk)
- Rivaroxaban specifically (higher GIB recurrence than other DOACs)
- Uncontrolled H. pylori infection
- Continued NSAID use
The fundamental principle: In non-shock GI bleeding post-stent, stop the DOAC definitively while carefully weighing whether aspirin can be safely continued based on time from stent placement and bleeding severity.